Aratana Therapeutics Inc. (NASDAQ:PETX) shares fell 1.9% during mid-day trading on Thursday . The stock traded as low as $6.76 and last traded at $6.78, with a volume of 118,686 shares trading hands. The stock had previously closed at $6.91.

Several brokerages have recently issued reports on PETX. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Aratana Therapeutics in a research note on Saturday, April 2nd. Zacks Investment Research lowered shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, March 19th. Jefferies Group reaffirmed a “buy” rating and issued a $12.00 target price on shares of Aratana Therapeutics in a research note on Saturday, April 2nd. Finally, William Blair reaffirmed an “outperform” rating on shares of Aratana Therapeutics in a research note on Tuesday, April 26th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $13.28.

The firm has a 50-day moving average of $6.67 and a 200-day moving average of $5.26. The stock’s market cap is $238.24 million.

Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.52) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.42) by $0.10. The company earned $0.17 million during the quarter, compared to analyst estimates of $0.13 million. During the same period in the previous year, the business posted ($0.26) earnings per share. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. On average, equities research analysts forecast that Aratana Therapeutics Inc. will post ($1.08) earnings per share for the current fiscal year.

In other Aratana Therapeutics news, insider Julia A. Stephanus sold 30,000 shares of the business’s stock in a transaction dated Tuesday, June 28th. The stock was sold at an average price of $6.25, for a total transaction of $187,500.00. Following the completion of the transaction, the insider now owns 127,503 shares of the company’s stock, valued at $796,893.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Peter Steven St sold 100,000 shares of the business’s stock in a transaction dated Friday, June 17th. The stock was sold at an average price of $6.26, for a total value of $626,000.00. Following the transaction, the chief executive officer now directly owns 717,793 shares of the company’s stock, valued at approximately $4,493,384.18. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Aratana Therapeutics stock. Jennison Associates increased its stake in shares of Aratana Therapeutics Inc. (NASDAQ:PETX) by 20.8% during the third quarter, according to its most recent filing with the SEC. The fund owned 4,146,200 shares of the biopharmaceutical company’s stock after buying an additional 714,413 shares during the period. Jennison Associates owned approximately 11.84% of Aratana Therapeutics worth $35,077,000 at the end of the most recent reporting period.

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions, such as pain and inflammation, stimulation of appetite, cancer and other serious diseases for dogs and cats.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.